阿立哌唑治疗帕利哌酮引起高泌乳素血症机制及研究进展
The Mechanism and Research Progress of Aripiprazole in the Treatment of Hyperprolactinemia Caused by Paliperidone
DOI: 10.12677/acm.2024.14123119, PDF,   
作者: 刘剑锋：西安医学院，研究生处，陕西 西安；西安市精神卫生中心，早期干预一科，陕西 西安；孙亚东：西安医学院，研究生处，陕西 西安；西安市精神卫生中心，妇女心理卫生一科，陕西 西安；戴尊孝*：西安医学院，研究生处，陕西 西安；西安市精神卫生中心，院长办公室，陕西 西安
关键词: 精神分裂症；高泌乳素血症；帕利哌酮；阿立哌唑；Schizophrenia； Hyperprolactinemia； Paliperidone； Aripiprazole
摘要: 精神分裂症是一种致残率较高的慢性疾病。帕利哌酮是常用的抗精神病药物，高泌乳素血症是使用帕利哌酮时常见的副作用。在这种情况下，联合使用阿立哌唑可以有效降低泌乳素水平。因此，了解高泌乳素血症的产生机制、帕利哌酮导致高泌乳素血症的机制以及阿立哌唑降低泌乳素水平的作用机制，对于改善患者的生存质量尤为重要。本文综述了阿立哌唑治疗帕利哌酮引起的高泌乳素血症的机制，旨在探索有效的精神专科治疗方案。
Abstract: Schizophrenia is a chronic disease with a high morbidity rate. Paliperidone is a commonly used antipsychotic drug; however, hyperprolactinemia is a common side effect of paliperidone. In this setting, coadministration with aripiprazole may be effective in reducing prolactin levels. Therefore, understanding the mechanism of hyperprolactinemia, the mechanism of paliperidone causing hyperprolactinemia, and the mechanism of aripiprazole reducing prolactin levels is particularly important to improve the quality of life of patients. This article reviews the mechanism of aripiprazole in the treatment of paliperidone-induced hyperprolactinemia, aiming to explore effective psychiatric treatment options.
文章引用：刘剑锋, 孙亚东, 戴尊孝. 阿立哌唑治疗帕利哌酮引起高泌乳素血症机制及研究进展[J]. 临床医学进展, 2024, 14(12): 569-574. https://doi.org/10.12677/acm.2024.14123119

参考文献

[1] Dawn, I.V. and Subramanyeshwar, R. (2023) The Epidemiology and Global Burden of Schizophrenia. The Journal of Clinical Psychiatry, 84, MS21078COM5.
[2] Piparva, K.G., Buch, J.G. and Chandrani, K.V. (2011) Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPD. Indian Journal of Psychological Medicine, 33, 153-157. [Google Scholar] [CrossRef] [PubMed]
[3] Halbreich, U. and Kahn, L.S. (2003) Hyperprolactinemia and Schizophrenia: Mechanisms and Clinical Aspects. Journal of Psychiatric Practice, 9, 344-353. [Google Scholar] [CrossRef] [PubMed]
[4] Austen, Y. and Mujeeb, U.S. (2020) Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series. The Primary Care Companion for CNS Disorders, 22, 19br02536.
[5] 中国神经科学学会精神病学基础与临床分会精神分裂症临床研究联盟. 抗精神病药所致高泌乳素血症干预对策的专家共识[J]. 中华精神科杂志, 2021, 54(3): 163-169.
[6] Nicholas, A.T. and Anne, K. (2015) Hyperprolactinemia. JAMA, 314, 1742-1743.
[7] Schlechte, J.A. (2003) Prolactinoma. New England Journal of Medicine, 349, 2035-2041. [Google Scholar] [CrossRef] [PubMed]
[8] Begon, E. and Bernard, V. (2022) Prolactin and Its Receptor: From Animal Models to Pituitary Pathophysiology. Biologie Aujourd’hui, 216, 105-110. [Google Scholar] [CrossRef] [PubMed]
[9] Fitzgerald, P. and Dinan, T.G. (2008) Prolactin and Dopamine: What Is the Connection? A Review Article. Journal of Psychopharmacology, 22, 12-19. [Google Scholar] [CrossRef] [PubMed]
[10] Kirsch, P., Kunadia, J., Shah, S. and Agrawal, N. (2022) Metabolic Effects of Prolactin and the Role of Dopamine Agonists: A Review. Frontiers in Endocrinology, 13, Article 1002320. [Google Scholar] [CrossRef] [PubMed]
[11] Lv, C., Mo, C., Liu, H., Wu, C., Li, Z., Li, J., et al. (2018) Dopamine D2-Like Receptors (DRD2 and DRD4) in Chickens: Tissue Distribution, Functional Analysis, and Their Involvement in Dopamine Inhibition of Pituitary Prolactin Expression. Gene, 651, 33-43. [Google Scholar] [CrossRef] [PubMed]
[12] Ángel, L.M., Buch, B., López, M.J., et al. (2022) Hormonal Alterations Due to Antipsychotic-Related Hyperprolactinemia. European Psychiatry, 65, S782.
[13] Katharina, W. (2021) Hyperprolactinemia in Women. Journal für Gynäkologische Endokrinologie/Österreich, 31, 102-105. [Google Scholar] [CrossRef] 
[14] Maggi, M., Buvat, J., Corona, G., Guay, A. and Torres, L.O. (2013) Hormonal Causes of Male Sexual Dysfunctions and Their Management (Hyperprolactinemia, Thyroid Disorders, GH Disorders, and DHEA). The Journal of Sexual Medicine, 10, 661-677. [Google Scholar] [CrossRef] [PubMed]
[15] Yun, S.J., Sang, H., Park, S.Y. and Chin, S.O. (2024) Effect of Hyperprolactinemia on Bone Metabolism: Focusing on Osteopenia/Osteoporosis. International Journal of Molecular Sciences, 25, Article 1474. [Google Scholar] [CrossRef] [PubMed]
[16] Katsuya, T., Katsumi, S. and Akio, S. (2019) Paliperidone/Risperidone. Reactions Weekly, 1466, 34.
[17] Minwalla, H.D., Wrzesinski, P., Desforges, A., Caskey, J., Wagner, B., Ingraffia, P., et al. (2021) Paliperidone to Treat Psychotic Disorders. Neurology International, 13, 343-358. [Google Scholar] [CrossRef] [PubMed]
[18] Montejo, Á.L., Arango, C., Bernardo, M., Carrasco, J.L., Crespo-Facorro, B., Cruz, J.J., et al. (2017) Multidisciplinary Consensus on the Therapeutic Recommendations for Iatrogenic Hyperprolactinemia Secondary to Antipsychotics. Frontiers in Neuroendocrinology, 45, 25-34. [Google Scholar] [CrossRef] [PubMed]
[19] Besnard, I., Auclair, V., Callery, G., Gabriel-Bordenave, C. and Roberge, C. (2014) Antipsychotic-Drug-Induced Hyperprolactinemia: Physiopathology, Clinical Features and Guidance. L’Encéphale, 40, 86-94. [Google Scholar] [CrossRef] [PubMed]
[20] Duval, F., Guillon, M., Mokrani, M., Crocq, M. and Garcia Duarte, F. (2008) Relationship between Prolactin Secretion, and Plasma Risperidone and 9-Hydroxyrisperidone Concentrations in Adolescents with Schizophreniform Disorder. Psychoneuroendocrinology, 33, 255-259. [Google Scholar] [CrossRef] [PubMed]
[21] Einarson, T.R., Hemels, M.E., Nuamah, I., Gopal, S., Coppola, D. and Hough, D. (2012) An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. Annals of Pharmacotherapy, 46, 1322-1330. [Google Scholar] [CrossRef] [PubMed]
[22] 金圭星, 王岚, 于鲁璐, 等. 不同剂型帕利哌酮对精神分裂症患者泌乳素水平影响的研究[C]//中华医学会第十一次全国精神医学学术会议暨第三届亚洲神经精神药理学术会议论文集. 2013: 149-150.
[23] Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T. and McQuade, R.D. (2021) Discovery Research and Development History of the Dopamine D2 Receptor Partial Agonists, Aripiprazole and Brexpiprazole. Neuropsychopharmacology Reports, 41, 134-143. [Google Scholar] [CrossRef] [PubMed]
[24] Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., et al. (2003) Aripiprazole, an Antipsychotic with a Novel Mechanism of Action, and Risperidone vs Placebo in Patients with Schizophrenia and Schizoaffective Disorder. Archives of General Psychiatry, 60, 681-690. [Google Scholar] [CrossRef] [PubMed]
[25] Soria-Chacartegui, P., Villapalos-García, G., Zubiaur, P., Abad-Santos, F. and Koller, D. (2021) Genetic Polymorphisms Associated with the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in Pharmacology, 12, Article 711940. [Google Scholar] [CrossRef] [PubMed]
[26] Bernagie, C., Danckaerts, M., Wampers, M. and De Hert, M. (2016) Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs, 30, 807-818. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, X., Mei, D., Lu, Z., Zhang, Y., Sun, Y., Lu, T., et al. (2023) Genome-wide Association Study Identified Six Loci Associated with Adverse Drug Reactions to Aripiprazole in Schizophrenia Patients. Schizophrenia, 9, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[28] Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L., Sibley, D.R., et al. (2003) Aripiprazole, a Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. Neuropsychopharmacology, 28, 1400-1411. [Google Scholar] [CrossRef] [PubMed]
[29] Ma, B., Zhao, W., Fan, H., Yun, Y., Qi, S., An, H., et al. (2023) Relationship between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 33, 27-33. [Google Scholar] [CrossRef] [PubMed]
[30] Tasaki, M., Yasui-Furukori, N., Kubo, K., Yokoyama, S., Shinozaki, M., Sugawara, N., et al. (2021) Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients with Schizophrenia. Therapeutic Drug Monitoring, 43, 589-592. [Google Scholar] [CrossRef] [PubMed]
[31] Joseph, S.P. (2016) Aripiprazole-Induced Hyperprolactinemia in a Young Female with Delusional Disorder. Indian Journal of Psychological Medicine, 38, 260-262. [Google Scholar] [CrossRef] [PubMed]
[32] Kelly, D.L., Wehring, H.J., Earl, A.K., Sullivan, K.M., Dickerson, F.B., Feldman, S., et al. (2013) Treating Symptomatic Hyperprolactinemia in Women with Schizophrenia: Presentation of the Ongoing DAAMSEL Clinical Trial (Dopamine Partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated Prolactin). BMC Psychiatry, 13, Article No. 214. [Google Scholar] [CrossRef] [PubMed]
[33] Snellen, M., Power, J., Blankley, G. and Galbally, M. (2016) Pharmacological Lactation Suppression with D2 Receptor Agonists and Risk of Postpartum Psychosis: A Systematic Review. Australian and New Zealand Journal of Obstetrics and Gynaecology, 56, 336-340. [Google Scholar] [CrossRef] [PubMed]
[34] Labad, J., Montalvo, I., González-Rodríguez, A., García-Rizo, C., Crespo-Facorro, B., Monreal, J.A., et al. (2020) Data of a Meta-Analysis on Pharmacological Treatment Strategies for Lowering Prolactin in People with a Psychotic Disorder and Hyperprolactinaemia. Data in Brief, 31, Article ID: 105904. [Google Scholar] [CrossRef] [PubMed]
[35] 黄锦, 朱丞. 帕利哌酮缓释片联合阿立哌唑对精神分裂症精神病性症状、认知功能和催乳素的影响[J]. 中华全科医学, 2022, 20(10): 1688-1690, 1791.
[36] 王飞, 车清磊, 王蕊, 等. 阿立哌唑对部分抗精神病药物所致高泌乳素血症疗效对比[J]. 中外医疗, 2022, 41(16): 67-70.
[37] 汪毅, 甘明远, 刘华清, 等. 帕利哌酮缓释片与阿立哌唑治疗青少年首发精神分裂症的疗效和催乳素变化[J]. 中国心理卫生杂志, 2019, 33(8): 592-597.
[38] 朱峰, 梅其一, 沈建红, 等. 阿立哌唑对帕利哌酮引起的高泌乳素水平的影响[C]//中华医学会第十次全国精神医学学术会议论文集. 2012: 140-141.
[39] Jiang, Q., Li, T., Zhao, L., Sun, Y., Mao, Z., Xing, Y., et al. (2024) Treatment of Antipsychotic-Induced Hyperprolactinemia: An Umbrella Review of Systematic Reviews and Meta-Analyses. Frontiers in Psychiatry, 15, Article 1337274. [Google Scholar] [CrossRef] [PubMed]
[40] Sá Esteves, P., Mota, D., Cerejeira, J., Mendes, F., et al. (2015) Low Doses of Adjunctive Aripiprazole as Treatment for Antipsychotic-Induced Hyperprolactinemia: A Literature Review. European Psychiatry, 30, 393.
[41] 陈景旭, 王宁, 卞清涛, 等. 阿立哌唑对利培酮所致高催乳素血症的疗效[J]. 临床精神医学杂志, 2009, 19(2): 127-129.
[42] Qiao, Y., Yang, F.Z., Li, C.B., et al. (2016) Add-On Effects of a Low-Dose Aripiprazole in Resolving Hyperprolactinemia Induced by Risperidone or Paliperidone. Psychiatry Research, 237, 83-89.
[43] Meng, M.L., Li, W., Zhang, S.W., et al. (2015) Using Aripiprazole to Reduce Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Currently Available Randomized Controlled Trials. Shanghai Arch Psychiatry, 27, 4-17.
[44] Krøigaard, S.M., Clemmensen, L., Tarp, S. and Pagsberg, A.K. (2022) A Meta-Analysis of Antipsychotic-Induced Hypo-and Hyperprolactinemia in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 32, 374-389. [Google Scholar] [CrossRef] [PubMed]
[45] Li, X., Tang, Y. and Wang, C. (2013) Adjunctive Aripiprazole versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials. PLOS ONE, 8, e70179. [Google Scholar] [CrossRef] [PubMed]
[46] Chen, J., Su, Y., Bian, Q., Wei, L., Zhang, R., Liu, Y., et al. (2015) Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study. Psychoneuroendocrinology, 58, 130-140. [Google Scholar] [CrossRef] [PubMed]

为你推荐